Martyn E. Caplin

Martyn E. Caplin, MD, FRCP is Professor of Gastroenterology and Neuroendocrinology at University College London and leads the Neuroendocrine Tumour Unit at the Royal Free Hospital, one of the largest NET centers in Europe. He is best known as the principal investigator of the CLARINET trial, the landmark phase III study that established lanreotide autogel (Somatuline Depot) as an antiproliferative agent in non-functional somatostatin receptor-positive NETs, leading to FDA and EMA approval for this indication in 2014. His clinical and research expertise encompasses the full spectrum of NET management, from somatostatin analogue therapy to carcinoid heart disease and hepatic metastases. Dr. Caplin has been a leading figure in ENETS, serving on multiple guideline committees and contributing to consensus standards for NET diagnosis, staging, and treatment. He established and oversees the UK and Ireland NET Society (UKINETS) registry, one of the largest prospective NET databases in Europe, enabling population-level analyses of NET epidemiology and treatment outcomes. His research group has characterized carcinoid heart disease — the fibrotic valvular complication of serotonin-secreting NETs — and contributed to echocardiographic screening protocols now embedded in NET management guidelines. An internationally recognized NET specialist, Dr. Caplin has published over 200 peer-reviewed articles and book chapters, and has mentored numerous NET specialists across the UK and internationally.